Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Total Liabilities (2016 - 2025)

Mimedx (MDXG) has disclosed Total Liabilities for 15 consecutive years, with $86.1 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 21.6% to $86.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $86.1 million through Dec 2025, up 21.6% year-over-year, with the annual reading at $86.1 million for FY2025, 21.6% up from the prior year.
  • Total Liabilities hit $86.1 million in Q4 2025 for Mimedx, up from $80.0 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $106.8 million in Q1 2021 to a low of $62.1 million in Q2 2024.
  • Historically, Total Liabilities has averaged $86.3 million across 5 years, with a median of $91.7 million in 2022.
  • Biggest five-year swings in Total Liabilities: tumbled 35.64% in 2024 and later increased 27.29% in 2025.
  • Year by year, Total Liabilities stood at $95.4 million in 2021, then increased by 1.65% to $96.9 million in 2022, then dropped by 0.61% to $96.3 million in 2023, then fell by 26.49% to $70.8 million in 2024, then rose by 21.6% to $86.1 million in 2025.
  • Business Quant data shows Total Liabilities for MDXG at $86.1 million in Q4 2025, $80.0 million in Q3 2025, and $74.5 million in Q2 2025.